Welcome to our dedicated page for LB Pharmaceuticals news (Ticker: LBRX), a resource for investors and traders seeking the latest updates and insights on LB Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LB Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LB Pharmaceuticals's position in the market.
LB Pharmaceuticals (Nasdaq: LBRX) appointed James Rawls, Pharm.D. as Senior Vice President of Regulatory Affairs on October 14, 2025.
Dr. Rawls brings 25+ years of regulatory leadership, with experience at Novartis, Sunovion, Sumitomo Pharma America, and Boston Biodevelopment, and has contributed to multiple global regulatory filings and product approvals. The company said his expertise will support advancing LB-102 into a Phase 3 schizophrenia trial and a Phase 2 bipolar depression trial planned for 2026.
LB Pharmaceuticals (Nasdaq: LBRX) will present three posters at the 38th ECNP Congress (Amsterdam, Oct 11-14, 2025) reporting analyses from the Phase 2 NOVA1 trial of LB-102 in acute schizophrenia.
A post-hoc cognitive analysis showed dose-dependent, statistically significant effect sizes versus placebo at 4 weeks: 0.26 (p=0.0476) at 50 mg, 0.41 (p=0.0027) at 75 mg and 0.66 (p=0.0018) at 100 mg in a completer population. Additional posters cover primary NOVA1 efficacy/safety results and a post-hoc analysis on negative symptoms. Posters go live on the company website on Oct 11, 2025.
LB Pharmaceuticals (NASDAQ:LBRX) has strengthened its Board of Directors with two strategic appointments following its IPO on September 10, 2025. The company has added William Kane, current President and CEO of Uniquity Bio with extensive commercialization experience, and Rekha Hemrajani, who brings significant financial and operational expertise.
These appointments come at a crucial time as LB Pharmaceuticals prepares to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026. LB-102 is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB Pharmaceuticals (NASDAQ:LBRX) has announced the pricing of its upsized initial public offering, offering 19,000,000 shares of common stock at $15.00 per share. The company expects to raise $285.0 million in gross proceeds before deducting underwriting costs and other expenses.
The IPO includes a 30-day option for underwriters to purchase up to 2,850,000 additional shares. Trading is set to commence on the Nasdaq Global Market on September 11, 2025, under the ticker symbol "LBRX". The offering is expected to close on September 12, 2025, with Leerink Partners, Piper Sandler, and Stifel serving as joint bookrunning managers.
FAQ
What is the current stock price of LB Pharmaceuticals (LBRX)?
What is the market cap of LB Pharmaceuticals (LBRX)?
